Consolidative Radiotherapy Versus Observation for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy
Institut de Cancerologie Lucien Neuwirth(0.0 mi away)Contact
+10 other location
This is a phase II, multicenter, randomized open-label and comparative study designed to
evaluate whether local consolidative radiotherapy improves overall survival as compared with
standard management in patients with limited metastatic urothelial bladder cancer and without
progression following first-line systemic therapy.
Each patient will be followed during 3 years from the date of randomization.
Clinical Study Identifier
Institut Claudius Regaud
Last Modified on
13 July 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.